Synribo (omacetaxine mepesuccinate; Teva/Hospira) is a subcutaneously formulated, semisynthetic form of homoharringtonine, a naturally occurring alkaloid. In vitro studies show that Synribo binds to the ribosomal A-site cleft, inhibiting synthesis of a number of key oncoproteins. These oncoproteins include mcl-1 (an apoptosis inhibitor), cyclin-D1 (a promoter of cell proliferation), and c-Myc (a cell differentiation inhibitor).
Synribo has suffered due to its late entrance into the chronic myeloid leukemia (CML) market and an unfavorable subcutaneous administration route compared to other marketed drugs. The drug has displayed activity against T315I mutation-positive disease, but Iclusig (ponatinib; Takeda/Incyte/Otsuka) displays similar activity and is available in an orally administered formulation. Therefore, Synribo will continue to see only minimal uptake in CML.
8 Figure 1: Synribo for CML – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Synribo for CML
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Synribo for CML
LIST OF TABLES
5 Table 1: Synribo drug profile
7 Table 2: Synribo pivotal trial data in CML
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.